Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial

Circulation

Volumn 111, Issue 13, 2005, Pages 1611-1618

  Lansky, Alexandra J ^a,h   Pietras, Cody ^a   Costa, Ricardo A ^a   Tsuchiya, Yoshihiro ^a   Brodie, Bruce R ^b   Cox, David A ^c   Aymong, Eve D ^a   Stuckey, Thomas D ^b   Garcia, Eulogio ^d   Tcheng, James E ^e   Mehran, Roxana ^a   Negoita, Manuela ^a   Fahy, Martin ^a   Cristea, Ecaterina ^a   Turco, Mark ^f   Leon, Martin B ^a   Grines, Cindy L ^g   Stone, Gregg W ^a  

^a Cardiovascular Research Foundation ^*  (United States)

^b MOSES CONE HEALTH SYSTEM   (United States)

^c Mid Carolina Cardiology   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f WASHINGTON ADVENTIST HOSPITAL   (United States)

^g WILLIAM BEAUMONT HOSPITAL   (United States)

^h CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Angioplasty; Coronary disease; Myocardial infarction; Stents; Women

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTOCOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIDINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BODY SURFACE; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DIABETES MELLITUS; FEMALE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SEX DIFFERENCE; STROKE; SURGICAL RISK; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BODY SIZE; FEMALE; HEART DISEASES; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RECURRENCE; RISK FACTORS; SEX FACTORS; STENTS; TREATMENT OUTCOME;

EID: 20244385465     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000160362.55803.40     Document Type: Article

References (27)

1. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy: GUSTO-I investigators. JAMA. 1996;275:777-782.
2. Malacrida R, Genoni M, Maggioni AP, Spataro V, Parish S, Palmer A, Collins R, Moccetti T. A comparison of the early outcome of acute myocardial infarction in women and men. N Engl J Med. 1998;338:8-14.
3. Vaccarino V, Berkman LF, Krumholz HM. Long-term outcome of myocardial infarction in women and men: a population perspective. Am J Epidemiol. 2000;152:965-973.
4. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol. 2001;88:848-852.
5. Stone GW, Grines CL, Browne KF, Marco J, Rothblaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N. Comparison of in-hospital outcomes in men and women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1995;75:987-992.
6. Tamis-Hoiland JE, Palazzo A, Stebbins AL, Slater JN, Boland J, Ellis SG, Hochman JS. (GUSTO II-B) Angioplasty Substudy. Am Heart J. 2004;147:133-139.
7. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van'T Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413-1419.
8. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
9. Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation. 2001;104:3034-3038.
10. Fisher LD, Kennedy JW, Davis KB, Maynard C, Fritz JK, Kaiser G, Myers WO. Association of sex, physical size, and operative mortality after coronary artery bypass in the coronary artery surgery study (CASS). J Thorac Cardiovasc Surg. 1982;84:334-341.
11. Peterson ED, Lansky AJ, Kramer J, Anstrom K, Lanzilotta MJ. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol. 2001;88:359-364.
12. McEniery PT, Hollman J, Knezinek V, Dorosti K, Franco I, Simpfendorfer C, Whitlow P. Comparative safety and efficacy of percutaneous transluminal coronary angioplasty in men and in women. Cathet Cardiovasc Diagn. 1987;13:364-371.
13. Ilia R, Bigham H, Brennan J, Cabin H, Cleman M, Remetz M. Predictors of coronary dissection following percutaneous transluminal coronary balloon angioplasty. Cardiology. 1994;85:229-234.
14. Ellis SG, Ajluni S, Arnold AZ, Popma JJ, Bittl JA, Eigler NL, Cowley MJ, Raymond RE, Safian RD, Whitlow PL. Increased coronary perforation in the new device era: incidence, classification, management, and outcome. Circulation. 1994;90:2725-2730.
15. Brodie BR, Stuckey TD, Wall TC, Kissling G, Hansen CJ, Muncy DB, Weintraub RA, Kelly TA. Importance of time to reperfusion for 30 day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
16. Berger PB, Ellis SG, Holmes DR, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship between delay in performing direct coronary angioplasty and early clinical outcomes in patients with acute myocardial infarction: results from the GUSTO-IIb trial. Circulation. 1999;100:14-20.
17. Brodie BR, Stone GW, Morice MC, Cox DA, Garcia E, Mattos LA, Boura J, O'Neill WW, Stuckey TD, Milks S, Lansky AJ, Grines CL; Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction trial. Am J Cardiol. 2001;88:1085-1090.
18. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist JC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide: Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. J Am Coll Cardiol. 1998;31:1518-1524.
19. Jacobs AK, Johnston JM, Haviland A, Brooks MM, Kelsey SF, Holmes DR Jr, Faxon DP, Williams DO, Detre KM. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol. 2002;39:1608-1614.
20. Taddei CF, Weintraub WS, Douglas JS Jr, Ghazzal Z, Mahoney E, Thompson T, King S 3rd. Influence of age on outcome after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1999;84:245-251.
21. Robertson T, Kennard ED, Mehta S, Popma JJ, Carrozza JP Jr, King SB 3rd, Holmes DR, Cowley MJ, Hornung CA, Kent KM, Roubin GS, Litvack F, Moses JW, Safian R, Desvigne-Nickens P, Detre KM. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol. 1997;80:26K-39K.
22. Welty FK, Lewis SM, Kowalker W, Shubrooks SJ Jr. Reasons for higher in-hospital mortality >24 hours after percutaneous transluminal coronary angioplasty in women compared with men. Am J Cardiol. 2001;88:473-477.
23. Moscucci M, Mansour KA, Kent KC, Kuntz RE, Senerchia C, Baim DS, Carrozza JP Jr. Peripheral vascular complications of directional coronary atherectomy and stenting: predictors, management, and outcome. Am J Cardiol. 1994;74:448-453.
24. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vaharian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
25. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG, and EPISTENT trials. J Am Coll Cardiol. 2000;36:381-386.
26. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoprotein IIb/IIIa inhibitor with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
27. Cantor WJ, Kaplan AL, Velianou JL, Sketch MH Jr, Bareness GW, Berger PB, Ohman EM. Effectiveness and safety of abciximab after failed tnrombolytic therapy. Am J Cardiol. 2001;87:439-442, A434.